National Institute of Infectious Diseases
A control tower
for national infectious diseases research
to realize national health security against global infectious diseases
International cooperation with the National Institute of Allergy and Infectious Diseases (NIAID) of the US
NIID is strengthening research competency for emerging and variant infectious diseases through cooperation between national research institutes of Korea and US.
Development of therapeutic antibodies for COVID-19, MERS-CoV, and SFTS (severe fever with thrombocytopenia syndrome)
Having jointly developed a neutralizing antibody treatment for COVID-19 (Regdanvimab), NIID is continuously promoting R&D of therapeutic antibodies for infectious diseases.
Development of therapeutic antibodies for COVID-19, MERS-CoV, and SFTS (severe fever with thrombocytopenia syndrome)
Having jointly developed a neutralizing antibody treatment for COVID-19 (Regdanvimab), NIID is continuously promoting R&D of therapeutic antibodies for infectious diseases.
Designation as WHO collaborating center
The department of Antimicrobial Resistance Research affiliated with NIID has been designated as a WHO Collaborating Center named "WHO Collaborating Centre for AMR Reference and One Health Research" in 2021 and contributes to the surveillance and overcoming of antimicrobial resistance.
Cooperation with Moderna of the US for SFTS vaccine development
NIID is conducting a joint international study to develop a candidate for the SFTS mRNA vaccine.
Cooperation with Moderna of the US for SFTS vaccine development
NIID is conducting a joint international study to develop a candidate for the SFTS mRNA vaccine.
